Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Genentech Raptiva To Undergo 5,000-Patient Postmarketing Safety Study

Dec 01 2003

• By The Pink Sheet

Related Content

Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive

Nov 03 2003

Raptiva Labeling Should Require Monitoring For Thrombocytopenia – Cmte.

Sep 22 2003

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window